Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 541-545

  Huq, Fazlul ^a   Yu, Jun Q ^a   Beale, Philip ^b   Chan, Charles ^c   Arzuman, Lalia ^a   Nessa, Meher U ^a   Mazumder, Mohammed E H ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

Cisplatin; Combination index; Drug combination; Drug resistance; Platinum DNA binding; Resveratrol; Synergism

Indexed keywords

ANETHOLE; BETULIC ACID; BORTEZOMIB; CAPSAICIN; CISPLATIN; CURCUMIN; EPIGALLOCATECHIN GALLATE; GENISTEIN; OXALIPLATIN; PACLITAXEL; PLATINUM; QUERCETIN; RESVERATROL; THYMOQUINONE; URSOLIC ACID; ANTINEOPLASTIC AGENT; PLANT MEDICINAL PRODUCT; PLATINUM COMPLEX; TUMOR MARKER;

CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CONFERENCE PAPER; DOSE RESPONSE; DRUG MECHANISM; FEMALE; GEL ELECTROPHORESIS; HUMAN; MASS SPECTROMETRY; OVARIAN CANCER CELL LINE; OVARY CANCER; APOPTOSIS; ARTICLE; COMBINATION INDEX; DRUG COMBINATION; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; METABOLISM; OVARY TUMOR; PATHOLOGY; PLATINUM-DNA BINDING; PROTEOMICS; SYNERGISM; TUMOR CELL CULTURE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CISPLATIN; COMBINATION INDEX; DRUG COMBINATION; DRUG RESISTANCE; PLATINUM-DNA BINDING; RESVERATROL; SYNERGISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PHYTOCHEMICALS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84897026499     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Gallion HH, Pieretti M, DePriest PD and van Nagell JR Jr.: The molecular basis of ovarian cancer. Cancer 76: 1992-1997, 1995.
2. Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mut Res 478: 23-43, 2001.
3. Loehrer PJ and Einhorn LH: Diagnosis and treatment: Drugs five years later. cisplatin. Ann Int Med 100(5): 704-713, 1984.
4. Pinedo HM and Schornagel JH: Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Plenum Press: New York, 1996.
5. Chan MM and Fong D: Overcoming ovarian cancer drug resistance with phytochemicals and other compounds. Prog Cancer Drug Resist Res 1-28, 2007.
6. Sarkar FH, Li Y, Sarkar FH and Li Y: Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66: 3347-3350, 2006.
7. Banerjee S, Padhye S, Azmi A, Wang Z, Philip PA, Kucuk O, Sarkar FH and Mohammad RM: Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer 62: 938-946, 2010.
8. Solomon Leigh A, Ali S, Banerjee S, Munkarah Adnan R, Morris Robert T and Sarkar Fazlul H: Sensitization of ovarian cancer cells to cisplatin by genistein: the role of NF-κB. J Ovarian Res 1, 9, 2008.
9. Chan MM, Fong D, Soprano KJ, Holmes WF, Heverling H, Chan MM, Fong D, Soprano KJ, Holmes WF and Heverling H: Inhibition of growth and sensitization to cisplatin-mediated killing of ovarian cancer cells by polyphenolic chemopreventive agents. J Cell Physiol 194: 63-70, 2003.
10. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71: 1397-1342, 2006.
11. Hu Y, Rahlfs S, Mersch-Sundermann V, Becker K, Hu Y, Rahlfs S, Mersch-Sundermann V and Becker K: Resveratrol modulates mRNA transcripts of genes related to redox metabolism and cell proliferation in non-small-cell lung carcinoma cells. Biol Chem 388: 207-219, 2007.
12. Sexton E, Van Themsche C, LeBlanc K, Parent S, Lemoine P, Asselin E, Sexton E, Van Themsche C, LeBlanc K, Parent S, Lemoine P and Asselin E: Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol Cancer 5: 45, 2006.
13. Golkar L, Ding XZ, Ujiki MB, Salabat MR, Kelly DL, Scholtens D, Fought AJ, Bentrem DJ, Talamonti MS, Bell RH, Adrian TE, Golkar L, Ding X-Z, Ujiki MB, Salabat MR, Kelly DL, Scholtens D, Fought AJ, Bentrem DJ, Talamonti MS, Bell RH and Adrian TE: Resveratrol inhibits pancreatic cancer cell proliferation through transcriptional induction of macrophage inhibitory cytokine-1. J Surg Res 138: 163-169, 2007.
14. Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig, R, Roessner A, Schneider-Stock R, Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A and Schneider-Stock R: Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol 25: 857-866, 2004.
15. Gali-Muhtasib H, Roessner A, Schneider-Stock R, Gali-Muhtasib H, Roessner A and Schneider-Stock R: Thymoquinone: a promising anti-cancer drug from natural sources. Int J Biochem Cell Biol 38: 1249-1253, 2006.
16. Yunos Nurhanan M, Beale P, Yu Jun Q and Huq F: Synergism from Sequenced Combinations of Curcumin and Epigallocatechin-3-gallate with Cisplatin in the Killing of Human Ovarian Cancer Cells. Anticancer Res 31: 1131-1140, 2011.
17. Alshehri A, Beale P, Yu JQ, Huq F, Alshehri A, Beale P, Yu JQ, and Huq F: Synergism from combination of cisplatin and a trans-platinum compound in ovarian cancer cell lines. Anticancer Res 30: 4547-4553, 2010.